TheStreet's Jim Cramer asks investors if Allergan has the ability to fight off Valeant. Cramer will be talking to David Pyott, CEO of Allergan, later today. Cramer finds it quite clear that Allergan is basing a lot of its independence on it's pipeline and he believes that if the pipeline is not as good as Pyott said it was, then investors are going to take their money and run. Cramer advises investors to sell half of their position in Allergan while letting the other half of their position run. Cramer says that he could see the stock closer to $120 or $125 but only if Valeant were not involved.
-- Get Cramer's top stocks with
Action Alerts PLUS
Trade with him FREE for 14-days.